Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

The importance of a homegrown biomanufacturing workforce to North Carolina’s swiftly growing life sciences industry was a ...

The transaction between Thermo Fisher and Sanofi is scheduled for completion in Q2 2025, subject to standard closing conditions.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025.

Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo ...

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product ...

Thermo Fisher updated its full-year adjusted EPS to a range of $22.22 to $22.84 from the previous outlook of $21.76 to $22.84 ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The stock is down by over 21% since the start of 2025; however, it continues to be a ...

Thermo Fisher on Wednesday raised the lower end of its annual profit forecast, banking on strong demand for its tools and ...